The landscape of alternative splicing in cervical squamous cell carcinoma

Peng Guo1, Dan Wang1, Jun Wu2

  • 1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing, People's Republic of China.

Oncotargets and Therapy
|January 8, 2015
PubMed
Abstract

Insights

Alternative splicing (AS) in cervical squamous cell carcinoma (CSCC) identified novel genes, KLHDC7B and SYCP2. These genes show potential as diagnostic and prognostic biomarkers for CSCC development and progression.

Area of Science:

  • Genomics
  • Molecular Biology
  • Cancer Research

Background:

  • Alternative splicing (AS) is crucial for protein diversity.
  • AS plays a significant role in cellular regulation and disease development.
  • Understanding AS in cancer is key to identifying new therapeutic targets.

Purpose of the Study:

  • To identify and characterize alternative splicing events in cervical squamous cell carcinoma (CSCC).
  • To investigate the potential of novel AS events as biomarkers for CSCC diagnosis and prognosis.

Main Methods:

  • RNA sequencing of four paired CSCC and adjacent nontumor tissues.
  • SpliceMap software for splicing junction detection.
  • Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.
  • Validation of AS events using reverse transcription-polymerase chain reaction (RT-PCR).

Main Results:

  • Identified 35 common, novel, and CSCC-specific alternative spliced genes.
  • Sixteen significantly enriched pathways were associated with AS.
  • Validated a novel 5'AS site in KLHDC7B and an exon-skipping site in SYCP2.
  • KLHDC7B AS correlated with differentiation and tumor size; SYCP2 AS correlated with invasion depth.

Conclusions:

  • KLHDC7B and SYCP2 genes with AS events are implicated in CSCC development and progression.
  • These AS events represent potential biomarkers for CSCC diagnosis and prognosis.

Related Concept Videos